Zhi Tong Cai Jing·2026-01-14 01:52Group 1 - China Biopharmaceutical (01177) shares rose over 5%, currently up 4.92% at HKD 7.24, with a trading volume of HKD 303 million [1] - The company announced a full acquisition of Hejiya, with the deal set to close on January 13, 2026, for a maximum base price of RMB 12 million, payable in cash and shares [1] - Hejiya specializes in the research and development of small interfering RNA (siRNA) innovative drugs, focusing on chronic diseases such as metabolic disorders, cardiovascular diseases, and neurological conditions [1] Group 2 - Hejiya has developed a differentiated delivery platform with independent intellectual property rights, featuring the MVIP (Multi-Valent Import Platform), which is the first clinically validated liver-targeted delivery platform capable of "one injection per year" for long-lasting treatment [2] - This platform addresses adherence issues in chronic disease treatment, which is a significant challenge in the industry [2]